Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

206.67 -0.02 (-0.01%)
Streaming Delayed Price Updated: 1:11 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades'
 
Via Benzinga
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Analyst Expectations For AbbVie's Future
 
Via Benzinga
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now
Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major patent concerns. 
Via Benzinga
Topics Intellectual Property
Is the Market Bullish or Bearish on AbbVie?
 
Via Benzinga
AbbVie Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
AbbVie Unusual Options Activity
 
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
 
Via Benzinga
This StoneCo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Is AbbVie Stock a Buy?
The pharmaceutical giant has been a roller coaster over the past several months. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
 
Via Benzinga
After The Tariff Flush, A Fresh Look At AbbVie Pharma
If ABBV has truly made a bottom, we should see it clear and close over 182. 
Via Talk Markets
Topics Stocks / Equities
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades'
 
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming?
Via The Motley Fool
Topics Economy Government World Trade
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday?
Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff. 
Via Benzinga
Topics World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Elliott Wave Technical Analysis: AbbVie Inc. - Wednesday, April 9
ABBV is currently showing a pronounced move down in both daily and 1-hour charts, suggesting a deeper ZigZag correction in play. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
83 84 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.